Literature DB >> 10869390

Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase.

W Xie1, J A Stribley, A Chatonnet, P J Wilder, A Rizzino, R D McComb, P Taylor, S H Hinrichs, O Lockridge.   

Abstract

Acetylcholinesterase (AChE; EC 3.1.1.7) is the primary terminator of nerve impulse transmission at cholinergic synapses and is believed to play an important role in neural development. Targeted deletion of four exons of the ACHE gene reduced AChE activity by half in heterozygous mutant mice and totally eliminated AChE activity in nullizygous animals. Butyrylcholinesterase (EC 3.1.1.8) activity was normal in AChE -/- mice. Although nullizygous mice were born alive and lived up to 21 days, physical development was delayed. The neuromuscular junction of 12-day-old nullizygous animals appeared normal in structure. Nullizygous mice were highly sensitive to the toxic effects of the organophosphate diisopropylfluorophosphate and to the butyrylcholinesterase-specific inhibitor bambuterol. These findings indicate that butyrylcholinesterase and possibly other enzymes are capable of compensating for some functions of AChE and that the inhibition of targets other than AChE by organophosphorus agents results in death.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869390

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  55 in total

Review 1.  Processing of cholinesterase-like α/β-hydrolase fold proteins: alterations associated with congenital disorders.

Authors:  Antonella De Jaco; Davide Comoletti; Noga Dubi; Shelley Camp; Palmer Taylor
Journal:  Protein Pept Lett       Date:  2012-02       Impact factor: 1.890

Review 2.  Molecular mechanism of active zone organization at vertebrate neuromuscular junctions.

Authors:  Hiroshi Nishimune
Journal:  Mol Neurobiol       Date:  2011-12-02       Impact factor: 5.590

Review 3.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

4.  Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase.

Authors:  Michelle N Ngamelue; Kohei Homma; Oksana Lockridge; Oluwatoyin A Asojo
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-08-10

Review 5.  Reassessment of the role of the central cholinergic system.

Authors:  Anna Hrabovska; Eric Krejci
Journal:  J Mol Neurosci       Date:  2013-11-10       Impact factor: 3.444

6.  Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.

Authors:  Andreas Wentrup; Wolfgang H Oertel; Richard Dodel
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

7.  Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis.

Authors:  Chien-Tsun Kuan; Jinli Chang; Jan-Eric Mansson; Jianjun Li; Charles Pegram; Pam Fredman; Roger E McLendon; Darell D Bigner
Journal:  BMC Dev Biol       Date:  2010-11-18       Impact factor: 1.978

8.  Differential regulation of lipid metabolism genes in the brain of acetylcholinesterase knockout mice.

Authors:  Huang-Quan Lin; Yan Wang; Kam-Leung Chan; Tsz-Ming Ip; Chi-Cheong David Wan
Journal:  J Mol Neurosci       Date:  2014-02-27       Impact factor: 3.444

9.  Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.

Authors:  María-Ximena Silveyra; Geneviève Evin; María-Fernanda Montenegro; Cecilio J Vidal; Salvador Martínez; Janetta G Culvenor; Javier Sáez-Valero
Journal:  Mol Cell Biol       Date:  2008-02-25       Impact factor: 4.272

10.  In vitro sensitivity of cholinesterases and [3H]oxotremorine-M binding in heart and brain of adult and aging rats to organophosphorus anticholinesterases.

Authors:  Nikita Mirajkar; Carey N Pope
Journal:  Biochem Pharmacol       Date:  2008-08-12       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.